.png)
The Global
Women’s Health Market is expected to witness a growth rate of
4-5% in the next five years. Growing incidence of women-centric
diseases (such as anaemia, endometriosis, osteoporosis, breast cancer,
menopause), the introduction of innovative new products for women’s health,
favourable government initiatives to curb population growth, and growing demand
for contraceptives to avoid unwanted pregnancies are some of the key factors
driving the women’s health market growth. However, adverse effects associated
with use of contraceptive drugs and devices, stringent regulatory approvals for
new products, and cultural and social barriers is likely to hinder the market’s
growth.
One-half of the world’s population is women and they account
for ~80% of consumer purchasing decisions in the healthcare industry. Women’s
Health is a branch of medicine that focuses on the prevention and
treatment of diseases that affect a health. It encompasses a range of drugs for
diseases related to women.
đź”— Want deeper insights?
Download the sample report:
https://meditechinsights.com/global-womens-health-market/request-sample/
Emerging Opportunities in Women’s Health Market
The rising prevalence of infectious and chronic diseases
amongst a large group of the female population is a key factor driving the
women’s health market. There is great potential to begin addressing these
conditions in new ways. Recent advances in genomics, tissue engineering,
artificial intelligence, and cell and gene therapy have synergized a new wave
of healthcare innovations that can be applied to create products and solutions
specific to women's conditions. For example, researchers are studying transcriptomics
(the study of RNA molecules in a cell) for treating elusive conditions such as
preeclampsia or preterm birth. On the other hand, tissue engineering is being
used to create uterine organoids to push the knowledge frontier on
endometriosis. Genomics is another research area that can help
researchers in realizing the potential of personalized medicine. There has been
extraordinary growth in terms of technology from predictive AI solutions to
modelling unique DNA profiles which uses machine learning algorithms to analyse
user data to provide unique, actionable insights and treatment plans related to
symptom progression. A favourable environment for research activities is
expected to further drive growth opportunities in this market.
“Women’s health is not a niche market; it includes much
more than just maternal or reproductive care. Indeed, women’s healthcare
presents enormous opportunities for value creation and for improving the lives
and livelihoods of women, with positive effects that redound across
society"- Executive Vice President, Global Operations and
Supply Chain, Women’s Health Company, United States
Growing incidence of women-centric diseases to Fuel
Market Growth
The rising prevalence of women-centric diseases such as
anaemia, endometriosis, osteoporosis, breast cancer, and menopause-related
conditions is significantly driving the women's health market. As these health
disorders become more common, there is an increasing demand for specialized
medical services, diagnostic tools, and treatments tailored to women's unique
health needs. For instance, there were 2,296,840 new cases of breast cancer in
2022 among women globally. The growing incidence of breast cancer has
led to higher demand for mammography and other breast imaging technologies, as
well as advanced surgical and pharmaceutical treatments. Endometriosis and
osteoporosis require targeted therapies and long-term management, further
expanding the market for drugs and medical devices designed specifically for
these conditions. Menopause management, including hormone replacement
therapies, also sees increased demand as more women seek relief from associated
symptoms. Moreover, heightened awareness and early diagnosis initiatives are
prompting more women to seek medical attention, contributing to the market's
growth. This trend is supported by governmental and non-governmental efforts to
improve women's health through education and funding, which enhances access to
necessary healthcare services. Consequently, the rising prevalence of these
diseases not only emphasizes the need for better healthcare solutions but also
propels the overall growth of the women's health market.
Product Type Segment Analysis
The women’s health market comprises two products like:
ACTONEL, YAZ (Yasmin, Yasminelle), FORTEO, Mirena, NuvaRing, ORTHO TRI-CY LO,
Premarin, Prolia, Reclast/Aclasta, XGEVA, Zometa, Others. The Prolia segment is
likely to lead the market and is projected to grow at the fastest rate over the
forecast period. Prolia, whose generic name is denosumab, is a medication used
in women's health for treating and preventing osteoporosis in postmenopausal
women. It is widely used for the treatment of osteoporosis in postmenopausal
women at high risk of fractures. Prolia has established a significant market
presence due to its effectiveness in reducing the incidence of fractures and
its biannual dosing regimen, which improves patient compliance compared to
other osteoporosis treatments.
The Minastrin 24 Fe segment is expected to grow at a
lucrative CAGR over the forecast period due to its user-friendly dosing
schedule and minimal side effects. It combines low-dose estrogen with progestin
and iron, which helps manage both birth control and iron deficiency, appealing
to women seeking dual benefits. The 24-day active pill regimen, with fewer
placebo days, is preferred for its convenience and reduced occurrence of
withdrawal bleeding. Additionally, increasing awareness of hormonal contraception's
benefits and growing demand for effective, well-tolerated contraceptive options
contribute to Minastrin 24 Fe's expanding market presence.
Application Type Segment Analysis
The women’s health market can be analyzed based on
application types, such as Hormonal infertility, Contraceptives, Postmenopausal
osteoporosis, Endometriosis & uterine fibroids, Menopause, Polycystic ovary
syndrome (PCOS), and Others. The contraceptives represent the largest segment.
The widespread use of contraceptives for both pregnancy prevention and
management of menstrual-related issues drives this large market segment.
Contraceptives benefit from extensive awareness, strong demand, and ongoing
innovation, which maintains their dominant position. The fastest-growing
segment is postmenopausal osteoporosis. The incidence of osteoporosis among
postmenopausal women is increasing continuously. This growth is driven by an
aging demographic, rising awareness of bone health, and advancements in
treatment options. Additionally, increased focus on preventive care and
proactive management of bone density is accelerating growth in this area. The
combination of a growing patient population and a heightened emphasis on
osteoporosis prevention and treatment supports its position as the
fastest-growing segment in the women’s health market.
Growth Strategies Adopted by Players to Establish Their
Foothold in the Market
Players operating in this market are adopting different
growth strategies such as new product launches and approvals to garner market
share. For instance,
- In
May 2024, The FDA approved Sandoz’s Jubbonti and Wyost
as interchangeable biosimilars to Prolia and Xgeva, respectively, for
treating certain types of osteoporosis and preventing bone events in
cancer. These approvals enhance treatment accessibility and demonstrate
the biosimilars' similar safety and efficacy to their reference products
- In
January 2024, Bayer Healthcare’s Mirena, a 52mg
Levonorgestrel IUD, received FDA approval for contraceptive to extend of
this device, for contraception only, to eight years. The approval is
particularly beneficial for younger perimenopausal women needing
contraception, while the license for treating heavy menstrual bleeding and
endometrial protection remains unchanged
- In
November 2023, Teva Pharmaceuticals received USFDA
of a generic version of Forteo (teriparatide injection) for osteoporosis
treatment. This approval enhances patient access to osteoporosis treatment
and supports Teva’s goal of maintaining its position as a leading generic
pharmaceutical company
The women’s health market is expected to gain further
momentum in the coming years due to impending patent cliff, rising R&D
investments, new product launches, and aggressive organic and inorganic growth
strategies followed by the players.
Gain a competitive edge-request a sample report now!
https://meditechinsights.com/global-womens-health-market/request-sample/
Competitive Landscape Analysis: Women’s Health Market
The global Women’s Health market is marked by the presence
of established market players such AbbVie Inc, Agile Therapeutics,
Amgen Inc., Eli Lilly & Company, Pfizer Inc., Merck & Co., Ferring
Pharmaceuticals, Mylan N.V., Blairex Laboratories, Apothecus Pharmaceutical,
Johnson & Johnson, LUPIN, Bayer AG, Novartis AG, Teva Pharmaceutical
Industries Ltd., Organon, Theramex and Allergan,
among others.
Future Outlook of the Women’s Health Market
The global Women’s Health market is expected to gain further
momentum in the coming years due to the Enhanced awareness about women's health
issues through education campaigns, social media, and government initiatives;
advancements in technology and medical research, and increasing government
funding and policies aimed at improving women's health. These factors
collectively contribute to the growth and evolution of the Women’s Health
market.
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment